GlaxoSmithKline's Belantamab Mafodotin Receives Marketing Approval in China

Stock News

04/17

On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in China. Based on earlier priority review information, the approved indication is for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC) originally developed by Seagen, which has since been acquired by Pfizer. In December 2009, GSK entered into an agreement with Seagen to secure the rights for research, development, production, and commercialization of the drug.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1177937236"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177937236\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177937236?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177937236","market":"fut","top_or_hot":-1,"title":"GlaxoSmithKline's Belantamab Mafodotin Receives Marketing Approval in China","media":"Stock News","content":"<p>On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in China. Based on earlier priority review information, the approved indication is for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC) originally developed by Seagen, which has since been acquired by Pfizer. In December 2009, GSK entered into an agreement with Seagen to secure the rights for research, development, production, and commercialization of the drug.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GlaxoSmithKline's Belantamab Mafodotin Receives Marketing Approval in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGlaxoSmithKline's Belantamab Mafodotin Receives Marketing Approval in China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-04-17 16:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in China. Based on earlier priority review information, the approved indication is for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC) originally developed by Seagen, which has since been acquired by Pfizer. In December 2009, GSK entered into an agreement with Seagen to secure the rights for research, development, production, and commercialization of the drug.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"","article_id":"1177937236","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177937236","pubTimestamp":1776415459,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU1829250122.USD":"高盛欧洲核心股票组合Acc","GSKH":"GSK plc ADRhedged","BK4588":"碎股","IPOS":"Renaissance International IPO ETF","BK4585":"ETF&股票定投概念","GSK":"葛兰素史克","BK4532":"文艺复兴科技持仓","GSK.UK":"葛兰素史克"},"translate_title":"葛兰素史克Belantamab Mafodotin在中国获上市批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":1,"GSK":1,"IPOS":1,"GSK.UK":1},"content_text":"On April 17, the website of China's National Medical Products Administration (NMPA) indicated that Belantamab mafodotin, developed by GlaxoSmithKline PLC (GSK.US), has received marketing approval in China. Based on earlier priority review information, the approved indication is for use in combination with bortezomib and dexamethasone to treat adult patients with multiple myeloma who have received at least one prior therapy. Belantamab mafodotin is a BCMA-targeted antibody-drug conjugate (ADC) originally developed by Seagen, which has since been acquired by Pfizer. In December 2009, GSK entered into an agreement with Seagen to secure the rights for research, development, production, and commercialization of the drug.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}